Brigham and Women’s Faulkner Hospital it now among a select number of institutions around the country, and the only hospital within the Partners HealthCare system, to offer a revolutionary approach to treating bladder cancer called Blue Light Cystoscopy with Cysview®.
This fall, Brigham Health urological surgeon Mark Preston, MD, MPH, started using Blue Light Cystoscopy with Cysview. “As a urologist specializing in treating patients with bladder cancer, we are always looking for advances in technology and treatment to provide the best possible care for our patients,” says Dr. Preston. “This is very promising technology that studies show can reduce rates of recurrence and hopefully will improve long term outcomes for patients as well.”
When symptoms and blood tests suggest that you may have bladder cancer, doctors perform a visual inspection of the interior wall of the bladder using a cystoscope—a thin tube with a light and video camera on the end—in a procedure called a cystoscopy.
With Blue Light Cystoscopy with Cysview doctors use a cystoscope equipped with both white and blue light. Before the procedure Cysview (hexaminolevulinate HCl) is instilled into the bladder. Cysview makes the cancer cells glow bright fluorescent pink in blue light and stand out against the blue of the healthy tissue. This results in the improvement of the visualization and detection of non-muscle invasive bladder cancer lesions.
Blue Light Cystoscopy with Cysview is FDA approved for use during surgery and for follow-up cystoscopies.
For an appointment, call 617-983-7500 or visit our website.
Looking for more news from BWFH? Go to News to find articles about health, updates to our programs and services and stories about staff and patients.
Go to News